Uses of monoclonal antibody 8h9

Abstract

This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof.

1 - 16 . (canceled) 
     
     
         17 . An isolated antibody that binds the same antigen as that of monoclonal antibody 8H9, wherein the Complementary Determining Region comprises SEQ ID NO:29 for CDR1, SEQ ID NO:30 for CDR2, SEQ ID NO:31 for CDR3 for the heavy chain, and SEQ ID NO:32 for the CDR1, SEQ ID NO:33 for CDR2, and SEQ ID NO:34 for CDR3 for the light chain, wherein said antibody is labeled. 
     
     
         18 . The antibody of  claim 17 , wherein said antibody is labelled by a radioisotope. 
     
     
         19 . The antibody of  claim 18 , wherein said radioisotope is Iodine. 
     
     
         20 . The antibody of  claim 18 , wherein said radioisotope is  124 Iodine. 
     
     
         21 . The antibody of  claim 18 , wherein said radioisotope is  131 Iodine. 
     
     
         22 . A composition comprising an effective amount of the antibody of  claim 17  and a suitable carrier. 
     
     
         23 . An isolated antibody that binds the same antigen as that of monoclonal antibody 8H9, wherein the Complementary Determining Region comprises SEQ ID NO:29 for CDR1, SEQ ID NO:30 for CDR2, SEQ ID NO:31 for CDR3 for the heavy chain, and SEQ ID NO:32 for the CDR1, SEQ ID NO:33 for CDR2, and SEQ ID NO:34 for CDR3 for the light chain, wherein said antibody is coupled to a cytotoxic agent. 
     
     
         24 . The antibody of  claim 23 , wherein said cytotoxic agent is a radioisotope. 
     
     
         25 . The antibody of  claim 24 , wherein said radioisotope is Iodine. 
     
     
         26 . The antibody of  claim 24 , wherein said radioisotope is  124 Iodine. 
     
     
         27 . The antibody of  claim 24 , wherein said radioisotope is  131 Iodine. 
     
     
         28 . A composition comprising an effective amount of the antibody of  claim 23  and a suitable carrier. 
     
     
         29 . A method for imaging a tumor in a subject comprising administering to the subject an antibody of  claim 17 . 
     
     
         30 . The method of  claim 29 , wherein said tumor is selected from the group consisting of neuroblastoma, glioma, desmoplastic small round cell tumor, and leptomeningeal cancer. 
     
     
         31 . A method for imaging a tumor in a subject comprising administering to the subject a composition of  claim 22 . 
     
     
         32 . The method of  claim 31 , wherein said tumor is selected from the group consisting of neuroblastoma, glioma, desmoplastic small round cell tumor, and leptomeningeal cancer. 
     
     
         33 . A method of reducing tumor cells in a subject comprising administering to the subject an antibody of  claim 23 . 
     
     
         34 . The method of  claim 33 , wherein said tumor is selected from the group consisting of neuroblastoma, glioma, desmoplastic small round cell tumor, and leptomeningeal cancer. 
     
     
         35 . A method of reducing tumor cells in a subject comprising administering to the subject a composition of  claim 28 . 
     
     
         36 . The method of  claim 35 , wherein said tumor is selected from the group consisting of neuroblastoma, glioma, desmoplastic small round cell tumor, and leptomeningeal cancer.